We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Healthcare Hit Again: Molina Cuts Guidance, Echoing Centene and UNH
Read MoreHide Full Article
Key Takeaways
MOH cut its 2025 EPS forecast to $21.50-$22.50, down 10.2% at mid-point from previous guidance.
Molina flagged elevated medical costs across all segments as the driver behind its revised outlook.
MOH shares have fallen 31.6% in 3 months, while the industry dropped 38.9% amid broader sector turmoil.
Molina Healthcare, Inc. (MOH - Free Report) became the latest health insurer to slash guidance and sound the alarm over rising medical costs and unpredictable utilization trends. It has lowered its full-year 2025 earnings guidance by 10.2% at mid-point, just days after Centene Corporation (CNC - Free Report) shocked the managed care industry by withdrawing its financial outlook.
The announcement, which comes two weeks ahead of Molina’s scheduled second-quarter earnings release, underscores the growing strain across the sector. The company cited elevated medical costs across all of its business lines as the key reason behind the downward revision.
Molina is the latest in a string of health insurers grappling with unexpected cost pressures. UnitedHealth Group Incorporated (UNH - Free Report) had already withdrawn its 2025 earnings guidance back in May. Centene followed UnitedHealth, citing persistently higher medical costs and unforeseen enrollment shifts. Molina’s pre-announcement further highlights the ripple effect spreading through the managed care space; each time one major insurer issues a warning, its peers have faced market fallout as well.
For the second quarter of 2025, Molina now expects adjusted earnings of around $5.50 per share. That’s well below the Zacks Consensus Estimate of $6.12 per share and reflects a 6.1% decline compared to the same period last year. Looking at the full year, the company now expects adjusted earnings per share to range between $21.50 and $22.50. This marks a sharp reduction from its prior forecast of at least $24.50 and falls below last year’s figure of $22.65. It also lags behind the Zacks Consensus Estimate, which was pegged at $24.44.
On the revenue front, the Zacks Consensus Estimate for Molina’s 2025 top line stood at $44.1 billion, which indicates an 8.4% increase from the prior year, a sign that demand remains robust even amid cost headwinds.
Image Source: Zacks Investment Research
Despite the near-term turbulence, Molina emphasized that its long-term strategic outlook remains unchanged. President and Chief Executive Officer Joseph Zubretsky reaffirmed the company’s confidence in its broader positioning, adding that even amid current challenges, the fundamentals of the business remain strong. Zubretsky hinted that the budget bill signed by President Donald Trump will not derail the company from its long-term trajectory.
Three-Month Price Performance
Shares of Molina have declined 31.6% over the past three months while the industry fell 38.9%. UnitedHealth and Centene saw even steeper losses, with shares tumbling 47.5% and 47.3%, respectively, during the same period. Meanwhile, the S&P 500 Index gained 15.1%, buoyed by strength in the tech-related sector.
From a valuation standpoint, Molina trades at a forward price-to-earnings ratio of 8.85, down from the industry average of 11.66. MOH currently carries a Value Score of A.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #2 (Buy).
Image: Bigstock
Healthcare Hit Again: Molina Cuts Guidance, Echoing Centene and UNH
Key Takeaways
Molina Healthcare, Inc. (MOH - Free Report) became the latest health insurer to slash guidance and sound the alarm over rising medical costs and unpredictable utilization trends. It has lowered its full-year 2025 earnings guidance by 10.2% at mid-point, just days after Centene Corporation (CNC - Free Report) shocked the managed care industry by withdrawing its financial outlook.
The announcement, which comes two weeks ahead of Molina’s scheduled second-quarter earnings release, underscores the growing strain across the sector. The company cited elevated medical costs across all of its business lines as the key reason behind the downward revision.
Molina is the latest in a string of health insurers grappling with unexpected cost pressures. UnitedHealth Group Incorporated (UNH - Free Report) had already withdrawn its 2025 earnings guidance back in May. Centene followed UnitedHealth, citing persistently higher medical costs and unforeseen enrollment shifts. Molina’s pre-announcement further highlights the ripple effect spreading through the managed care space; each time one major insurer issues a warning, its peers have faced market fallout as well.
For the second quarter of 2025, Molina now expects adjusted earnings of around $5.50 per share. That’s well below the Zacks Consensus Estimate of $6.12 per share and reflects a 6.1% decline compared to the same period last year. Looking at the full year, the company now expects adjusted earnings per share to range between $21.50 and $22.50. This marks a sharp reduction from its prior forecast of at least $24.50 and falls below last year’s figure of $22.65. It also lags behind the Zacks Consensus Estimate, which was pegged at $24.44.
On the revenue front, the Zacks Consensus Estimate for Molina’s 2025 top line stood at $44.1 billion, which indicates an 8.4% increase from the prior year, a sign that demand remains robust even amid cost headwinds.
Despite the near-term turbulence, Molina emphasized that its long-term strategic outlook remains unchanged. President and Chief Executive Officer Joseph Zubretsky reaffirmed the company’s confidence in its broader positioning, adding that even amid current challenges, the fundamentals of the business remain strong. Zubretsky hinted that the budget bill signed by President Donald Trump will not derail the company from its long-term trajectory.
Three-Month Price Performance
Shares of Molina have declined 31.6% over the past three months while the industry fell 38.9%. UnitedHealth and Centene saw even steeper losses, with shares tumbling 47.5% and 47.3%, respectively, during the same period. Meanwhile, the S&P 500 Index gained 15.1%, buoyed by strength in the tech-related sector.
Price Performance Comparison – MOH, UNH, CNC, Industry & S&P 500
Molina’s Valuation
From a valuation standpoint, Molina trades at a forward price-to-earnings ratio of 8.85, down from the industry average of 11.66. MOH currently carries a Value Score of A.
The stock currently carries a Zacks Rank #2 (Buy).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.